| Nov 21 |
Avalon Globocare regains Nasdaq compliance
|
| Nov 21 |
Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements
|
| Nov 18 |
(ALBT) - Analyzing Avalon Globocare's Short Interest
|
| Nov 18 |
Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
|
| Nov 15 |
Avalon GloboCare Third Quarter 2024 Earnings: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)
|
| Nov 4 |
Top Premarket Decliners
|
| Oct 31 |
Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
|
| Oct 25 |
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
|
| Oct 25 |
EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer
|
| Oct 24 |
Avalon GloboCare announces 1-for-15 reverse stock split as part of Nasdaq compliance plan
|
